Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF

被引：0
|
作者：
Joseph Gathe
Jose R. Arribas
Jan Van Lunzen
Will Garner
Rebecca M. Speck
Randall Bender
Sanatan Shreay
Thai Nguyen
机构：
[1] Therapeutic Concepts,
[2] PA,undefined
[3] Hospital La Paz,undefined
[4] IdiPaz,undefined
[5] Universitaetsklinikum Hamburg-Eppendorf,undefined
[6] Gilead Sciences,undefined
[7] Inc.,undefined
[8] Evidera,undefined
来源：
The Patient - Patient-Centered Outcomes Research | 2015年 / 8卷
关键词：
Physical Component Summary; Mental Component Summary; Tenofovir Disoproxil Fumarate; Mental Component Summary Score; Emtricitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：445 / 454
页数：9
相关论文
共 33 条
  • [31] A phase 3b open-label pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single tablet regimen (STR) in virologically suppressed HIV-1 infected adults harbouring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)
    Perez-Valero, I.
    Llibre, J. M.
    Pulido, F.
    Molina, J-M
    Esser, S.
    McNicholl, I.
    Lorgeoux, R-P
    Piontkowsky, D.
    Sathia, L.
    Haubrich, R.
    HIV MEDICINE, 2018, 19 : S21 - S21
  • [32] A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)
    Valero, I. Perez
    Llibre, J. M.
    Lazzarin, A.
    Di Perri, G.
    Pulido, F.
    Molina, J. -M.
    Esser, S.
    McNicholl, I.
    Lorgeoux, R. -P.
    Margot, N.
    Shao, Y.
    Piontkowsky, D.
    Das, M.
    Haubrich, R.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 6 - 7
  • [33] A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring NRTI resistance mutations M184V/I +/- TAMs (GS-US-292-1824): week 24 results
    Perez-Valero, I.
    Llibre, J. M.
    Lazzarin, A.
    Di Perri, G.
    Pulido, F.
    Molina, J-M
    Esser, S.
    Margot, N.
    Shao, Y.
    Piontkowsky, D.
    Das, M.
    McNicholl, I.
    Haubrich, R.
    HIV MEDICINE, 2019, 20 : 170 - 171
1234